Calcipotriol With Betamethasone Dipropionate, Ointment
Recommended DermatologyRestricted BenefitLater-line line
chronic stable plaque type psoriasis vulgaris in patients not adequately controlled with either calcipotriol or potent topical corticosteroid monotherapy
1
Submissions
2009–09
On the record
—
ICER range
Cost-min
Cost basis
Decisions on record
- Meeting Nov 2025 Recommended Chronic stable plaque type psoriasis vulgaris of scalp and body
- Meeting Jul 2025 Recommended Chronic stable plaque psoriasis vulgaris inadequately responding to potent topical corticosteroid
- Meeting Jul 2023 Not recommended Chronic stable plaque type psoriasis vulgaris
- Meeting Nov 2010 Recommended Psoriasis no PSD
- Meeting Jul 2009 Recommended Psoriasis
Access path
- Jul 2009Recommended · restricted
vs calcipotriol and betamethasone dipropionate individual…
- PBS listing · Restricted Benefit
RecommendedDeferredNot recommended
Cost-effectiveness
Cost minimisation analysis performed; no ICER calculated
The PBAC recommended the listing of calcipotriol with betamethasone ointment (50 micrograms-500 micrograms (base) per g) as a restricted benefit on a cost minimisation basis compared with the individual components for use in the treatment of chronic stable plaque type psoriasis in a patient not adequately controlled with either calcipotriol or potent topical corticosteroid monotherapy. PBAC · 2009
Cost-effectiveness accepted
Decision context
Populationchronic stable plaque type psoriasis vulgaris in patients not adequately controlled with either calcipotriol or potent topical corticosteroid monotherapy
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Jul 2009 | Recommended · restricted | calcipotriol and betamethasone dipropionate individual components given concomitantly | — | RCT · PASI (Psoriasis Area and Severity Index) |
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to patients with inadequate response to prior calcipotriol or potent topical corticosteroid monotherapy; TGA label has no such treatment-failure requirement.